{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:14:31Z","timestamp":1790810071999,"version":"4.1.0"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073894"],"award-info":[{"award-number":["82073894"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"New Medicine Clinical Research Fund","award":["4246Z512"],"award-info":[{"award-number":["4246Z512"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ceftazidime\/avibactam (CZA) is recognized as an efficacious treatment modality against multidrug-resistant Pseudomonas aeruginosa. Nevertheless, it encounters the challenge of escalating antimicrobial resistance. Employing combination regimens involving ceftazidime\/avibactam may confer advantages.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Checkerboard titration, time-kill assays, and an in vitro pharmacodynamic model were employed to investigate the effectiveness of ceftazidime\/avibactam alone and in combination in vitro. Additionally, an intraperitoneal infection mouse model was established to assess the efficacy of combination therapy in vivo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the in vitro pharmacodynamic model, administration of ceftazidime\/avibactam plus polymyxin B resulted in a significant reduction in colony-forming units of all four strains, whereas ceftazidime\/avibactam plus aztreonam only reduced the colonies of three strains. Significant or trending declines in mortality and tissue colony counts of infected mice were observed in groups treated with ceftazidime\/avibactam plus polymyxin B. Conversely, ceftazidime\/avibactam combined with aztreonam only reduced mortality and tissue colonies in MBL-positive P.aeruginosa-infected mice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Combining ceftazidime\/avibactam with polymyxin B might represent a potentially effective option against MDR-P.aeruginosa. Although the synergistic effect in vitro might not be readily apparent due to the potent bactericidal effect of aztreonam alone, the combination of ceftazidime\/avibactam and aztreonam demonstrated promising synergistic effects on MBL-positive P.aeruginosa strains in vivo.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf495","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T12:57:45Z","timestamp":1766581065000},"source":"Crossref","is-referenced-by-count":2,"title":["Ceftazidime\/avibactam: a potent arsenal against multidrug-resistant\n                    <i>Pseudomonas aeruginosa<\/i>\n                    -unveiling\n                    <i>in vitro<\/i>\n                    and\n                    <i>in vivo<\/i>\n                    strategies"],"prefix":"10.1093","volume":"81","author":[{"given":"Jiaju","family":"Zhuo","sequence":"first","affiliation":[{"name":"Center of Medicine Clinical Research, Department of Pharmacy, Medical Supplies Center of PLA General Hospital , Beijing 10083 ,","place":["China"]},{"name":"Department of Pharmacy, The Third People\u2019s Hospital of Chengdu , Chengdu 610031 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Xu","sequence":"additional","affiliation":[{"name":"Center of Medicine Clinical Research, Department of Pharmacy, Medical Supplies Center of PLA General Hospital , Beijing 10083 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulong","family":"Chi","sequence":"additional","affiliation":[{"name":"Center of Medicine Clinical Research, Department of Pharmacy, Medical Supplies Center of PLA General Hospital , Beijing 10083 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Zhang","sequence":"additional","affiliation":[{"name":"Center of Medicine Clinical Research, Department of Pharmacy, Medical Supplies Center of PLA General Hospital , Beijing 10083 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanshuang","family":"Fu","sequence":"additional","affiliation":[{"name":"Center of Medicine Clinical Research, Department of Pharmacy, Medical Supplies Center of PLA General Hospital , Beijing 10083 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehua","family":"Chen","sequence":"additional","affiliation":[{"name":"Center of Medicine Clinical Research, Department of Pharmacy, Medical Supplies Center of PLA General Hospital , Beijing 10083 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beibei","family":"Liang","sequence":"additional","affiliation":[{"name":"Center of Medicine Clinical Research, Department of Pharmacy, Medical Supplies Center of PLA General Hospital , Beijing 10083 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6687-9984","authenticated-orcid":false,"given":"Yun","family":"Cai","sequence":"additional","affiliation":[{"name":"Center of Medicine Clinical Research, Department of Pharmacy, Medical Supplies Center of PLA General Hospital , Beijing 10083 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"2026011902093709100_dkaf495-B1","doi-asserted-by":"publisher","first-page":"106772","DOI":"10.1016\/j.ijantimicag.2023.106772","article-title":"In vitro activity of ceftolozane\/tazobactam against multidrug-resistant Pseudomonas aeruginosa from patients in Western Europe: SMART 2017\u20132020","volume":"61","author":"Karlowsky","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"2026011902093709100_dkaf495-B2","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1186\/s12879-025-10927-1","article-title":"The causes and outcomes of nosocomial meningitis by pathogens for which new antibiotics are urgently needed","volume":"25","author":"Ye","year":"2025","journal-title":"BMC Infect Dis"},{"key":"2026011902093709100_dkaf495-B3","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.ajic.2016.08.007","article-title":"International nosocomial infection control consortium report, data summary of 50 countries for 2010\u20132015: device-associated module","volume":"44","author":"Rosenthal","year":"2016","journal-title":"Am J Infect Control"},{"key":"2026011902093709100_dkaf495-B4","doi-asserted-by":"publisher","first-page":"100628","DOI":"10.1016\/j.lanwpc.2022.100628","article-title":"Association between antibiotic resistance and increasing ambient temperature in China: an ecological study with nationwide panel data","volume":"30","author":"Li","year":"2022","journal-title":"Lancet Reg Health West Pac"},{"key":"2026011902093709100_dkaf495-B5","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1007\/s40265-021-01635-6","article-title":"The epidemiology and pathogenesis and treatment of Pseudomonas aeruginosa infections: an update","volume":"81","author":"Reynolds","year":"2021","journal-title":"Drugs"},{"key":"2026011902093709100_dkaf495-B6","doi-asserted-by":"publisher","first-page":"e02762-17","DOI":"10.1128\/AEM.02762-17","article-title":"Pseudomonas aeruginosa biofilm antibiotic resistance gene ndvB expression requires the RpoS stationary-phase sigma factor","volume":"84","author":"Hall","year":"2018","journal-title":"Appl Environ Microbiol"},{"key":"2026011902093709100_dkaf495-B7","doi-asserted-by":"publisher","first-page":"e000370","DOI":"10.1099\/mgen.0.000370","article-title":"Antibiotic resistance in Pseudomonas aeruginosa and adaptation to complex dynamic environments","volume":"6","author":"Sommer","year":"2020","journal-title":"Microb Genom"},{"key":"2026011902093709100_dkaf495-B8","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1093\/cid\/ciy378","article-title":"Difficult-to-treat resistance in Gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents","volume":"67","author":"Kadri","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2026011902093709100_dkaf495-B9","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/cid\/ciac268","article-title":"Infectious Diseases Society of America 2022 guidance on the treatment of extended-spectrum \u03b2-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa)","volume":"75","author":"Tamma","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026011902093709100_dkaf495-B10","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1097\/QCO.0000000000000685","article-title":"Treatment of extended-spectrum \u03b2-lactamases infections: what is the current role of new \u03b2-lactams\/\u03b2-lactamase inhibitors?","volume":"33","author":"Bassetti","year":"2020","journal-title":"Curr Opin Infect Dis"},{"key":"2026011902093709100_dkaf495-B11","doi-asserted-by":"publisher","first-page":"e1571","DOI":"10.1002\/wsbm.1571","article-title":"Molecular mechanisms underlying bacterial resistance to ceftazidime\/avibactam","volume":"14","author":"Xiong","year":"2022","journal-title":"WIREs Mech Dis"},{"key":"2026011902093709100_dkaf495-B12","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s40265-013-0013-7","article-title":"Ceftazidime-avibactam: a novel cephalosporin\/\u03b2-lactamase inhibitor combination","volume":"73","author":"Zhanel","year":"2013","journal-title":"Drugs"},{"key":"2026011902093709100_dkaf495-B13","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1128\/AAC.03042-15","article-title":"In Vitro susceptibility to ceftazidime-avibactam of carbapenem-nonsusceptible Enterobacteriaceae isolates collected during the INFORM Global Surveillance Study (2012 to 2014)","volume":"60","author":"de Jonge","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011902093709100_dkaf495-B14","doi-asserted-by":"publisher","first-page":"1156651","DOI":"10.3389\/fcimb.2023.1156651","article-title":"Assessment of mortality-related risk factors and effective antimicrobial regimens for treatment of bloodstream infections caused by carbapenem-resistant Pseudomonas aeruginosa in patients with hematological diseases","volume":"13","author":"Zhen","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"2026011902093709100_dkaf495-B15","doi-asserted-by":"publisher","first-page":"387.e7","DOI":"10.1016\/j.cmi.2022.10.013","article-title":"A novel KPC-113 variant conferring carbapenem and ceftazidime-avibactam resistance in a multidrug-resistant Pseudomonas aeruginosa isolate","volume":"29","author":"Yang","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"2026011902093709100_dkaf495-B16","doi-asserted-by":"publisher","first-page":"1007162","DOI":"10.3389\/fphar.2022.1007162","article-title":"Role of the multi-drug efflux systems on the baseline susceptibility to ceftazidime\/avibactam and ceftolozane\/tazobactam in clinical isolates of non-carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa","volume":"13","author":"Contreras-G\u00f3mez","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026011902093709100_dkaf495-B17","doi-asserted-by":"publisher","first-page":"106867","DOI":"10.1016\/j.ijantimicag.2023.106867","article-title":"In vitro activities of ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam and other comparators against Pseudomonas aeruginosa isolates with discrepant resistance to carbapenems: data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2012\u20132021","volume":"62","author":"Lee","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"2026011902093709100_dkaf495-B18","doi-asserted-by":"publisher","first-page":"e01814-18","DOI":"10.1128\/AAC.01814-18","article-title":"In Vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa collected in Latin American countries: results from the INFORM Global Surveillance Program, 2012 to 2015","volume":"63","author":"Karlowsky","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011902093709100_dkaf495-B19","doi-asserted-by":"publisher","first-page":"739","DOI":"10.3760\/cma.j.cn112147-20220407-00290","article-title":"Chinese expert consensus on the management of lower respiratory tract infections of Pseudomonas aeruginosa in adults(2022)","volume":"45","author":"Pulmonary Infection Assembly of Chinese Thoracic Society","year":"2022","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"2026011902093709100_dkaf495-B20","doi-asserted-by":"publisher","first-page":"e169","DOI":"10.1093\/cid\/ciaa1478","article-title":"Infectious Diseases Society of America guidance on the treatment of extended-spectrum beta-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa)","volume":"72","author":"Tamma","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026011902093709100_dkaf495-B21","doi-asserted-by":"publisher","first-page":"e00115-20","DOI":"10.1128\/CMR.00115-20","article-title":"New \u03b2-lactam-\u03b2-lactamase inhibitor combinations","volume":"34","author":"Yahav","year":"2020","journal-title":"Clin Microbiol Rev"},{"key":"2026011902093709100_dkaf495-B22","doi-asserted-by":"publisher","first-page":"105517","DOI":"10.1016\/j.micpath.2022.105517","article-title":"Evaluation of the in vitro synergy of polymyxin B-based combinations against polymyxin B -resistant gram-negative bacilli","volume":"166","author":"Li","year":"2022","journal-title":"Microb Pathog"},{"key":"2026011902093709100_dkaf495-B23","doi-asserted-by":"publisher","first-page":"858","DOI":"10.3390\/antibiotics12050858","article-title":"Synergistic activity of cefiderocol in combination with piperacillin-tazobactam, fosfomycin, ampicillin-sulbactam, imipenem-relebactam and ceftazidime-avibactam against carbapenem-resistant Gram-negative Bacteria","volume":"12","author":"Palombo","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"2026011902093709100_dkaf495-B24","doi-asserted-by":"publisher","first-page":"366","DOI":"10.3389\/fmicb.2019.00366","article-title":"MexXY multidrug efflux system is more frequently overexpressed in ciprofloxacin resistant French clinical isolates compared to hospital environment ones","volume":"10","author":"Serra","year":"2019","journal-title":"Front Microbiol"},{"key":"2026011902093709100_dkaf495-B25","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1128\/AAC.01645-10","article-title":"Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study","volume":"55","author":"Cabot","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011902093709100_dkaf495-B26","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing\u2014TwentySixth Edition: M100","author":"CLSI","year":"2016"},{"key":"2026011902093709100_dkaf495-B27","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13756-018-0435-9","article-title":"In vitro and in vivo bactericidal activity of ceftazidime-avibactam against carbapenemase-producing Klebsiella pneumoniae","volume":"7","author":"Zhang","year":"2018","journal-title":"Antimicrob Resist Infect Control"},{"key":"2026011902093709100_dkaf495-B28","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s40261-015-0347-x","article-title":"A randomized, phase I study to assess the safety, tolerability and pharmacokinetics of ceftazidime-avibactam in healthy Chinese subjects","volume":"36","author":"Li","year":"2016","journal-title":"Clin Drug Investig"},{"key":"2026011902093709100_dkaf495-B29","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/S0149-2918(01)80103-X","article-title":"Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients","volume":"23","author":"Smith","year":"2001","journal-title":"Clin Ther"},{"key":"2026011902093709100_dkaf495-B30","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jinf.2021.01.006","article-title":"Acute toxicity is a dose-limiting factor for intravenous polymyxin B: a safety and pharmacokinetic study in healthy Chinese subjects","volume":"82","author":"Liu","year":"2021","journal-title":"J Infect"},{"key":"2026011902093709100_dkaf495-B31","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1590\/0037-8682-0081-2014","article-title":"Colistin and anti-Gram-positive bacterial agents against Acinetobacter baumannii","volume":"47","author":"Liu","year":"2014","journal-title":"Rev Soc Bras Med Trop"},{"key":"2026011902093709100_dkaf495-B32","doi-asserted-by":"publisher","first-page":"e01989-18","DOI":"10.1128\/AAC.01989-18","article-title":"Dose optimization of colistin combinations against carbapenem-resistant Acinetobacter baumannii from patients with hospital-acquired pneumonia in China by using an In Vitro pharmacokinetic\/pharmacodynamic model","volume":"63","author":"Bian","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011902093709100_dkaf495-B33","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s15010-022-01876-x","article-title":"Update of clinical application in ceftazidime-avibactam for multidrug-resistant Gram-negative bacteria infections","volume":"50","author":"Zhen","year":"2022","journal-title":"Infection"},{"key":"2026011902093709100_dkaf495-B34","doi-asserted-by":"publisher","first-page":"e0040523","DOI":"10.1128\/aac.00405-23","article-title":"Ceftolozane-tazobactam versus ceftazidime-avibactam for the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa: a multicenter cohort study","volume":"67","author":"Almangour","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011902093709100_dkaf495-B35","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1089\/mdr.2019.0463","article-title":"In Vitro activity of ceftazidime-avibactam alone and in combination with amikacin against colistin-resistant Gram-negative pathogens","volume":"27","author":"Chen","year":"2021","journal-title":"Microb Drug Resist"},{"key":"2026011902093709100_dkaf495-B36","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1093\/jac\/dkz228","article-title":"Potentiation of \u03b2-lactam antibiotics and \u03b2-lactam\/\u03b2-lactamase inhibitor combinations against MDR and XDR Pseudomonas aeruginosa using non-ribosomal tobramycin-cyclam conjugates","volume":"74","author":"Idowu","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2026011902093709100_dkaf495-B37","doi-asserted-by":"publisher","first-page":"106967","DOI":"10.1016\/j.ijantimicag.2023.106967","article-title":"Activity of polymyxin B combinations against genetically well-characterised Klebsiella pneumoniae producing NDM-1 and OXA-48-like carbapenemases","volume":"62","author":"Olsson","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"2026011902093709100_dkaf495-B38","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.3390\/antibiotics10081012","article-title":"The revival of aztreonam in combination with avibactam against metallo-\u03b2-lactamase-producing Gram-negatives: a systematic review of in vitro studies and clinical cases","volume":"10","author":"Mauri","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"2026011902093709100_dkaf495-B39","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/14787210.2023.2184346","article-title":"Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy?","volume":"21","author":"Ardebili","year":"2023","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2026011902093709100_dkaf495-B40","doi-asserted-by":"publisher","first-page":"107113","DOI":"10.1016\/j.ijantimicag.2024.107113","article-title":"Activity of aztreonam-avibactam against Enterobacterales resistant to recently approved beta-lactamase inhibitor combinations collected in Europe, Latin America, and the Asia-Pacific Region (2020\u20132022)","volume":"63","author":"Sader","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"2026011902093709100_dkaf495-B41","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3390\/pharmaceutics16020185","article-title":"Potentiation of antibiotic activity of aztreonam against metallo-\u03b2-lactamase-producing multidrug-resistant Pseudomonas aeruginosa by 3-O-substituted difluoroquercetin derivatives","volume":"16","author":"Lee","year":"2024","journal-title":"Pharmaceutics"},{"key":"2026011902093709100_dkaf495-B42","doi-asserted-by":"publisher","first-page":"7107","DOI":"10.2147\/IDR.S385240","article-title":"In vitro and in vivo antimicrobial activities of ceftazidime\/avibactam alone or in combination with aztreonam against carbapenem-resistant Enterobacterales","volume":"15","author":"Lu","year":"2022","journal-title":"Infect Drug Resist"},{"key":"2026011902093709100_dkaf495-B43","doi-asserted-by":"publisher","first-page":"6311","DOI":"10.1128\/AAC.03572-14","article-title":"Impact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the ceftolozane in vivo pharmacokinetic\/pharmacodynamic target","volume":"58","author":"Lepak","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011902093709100_dkaf495-B44","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/antibiotics8010024","article-title":"Polymyxin acute kidney injury: dosing and other strategies to reduce toxicity","volume":"8","author":"Nation","year":"2019","journal-title":"Antibiotics (Basel)"},{"key":"2026011902093709100_dkaf495-B45","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/s41429-023-00631-0","article-title":"In vitro activity of ceftazidime\/avibactam, imipenem\/relebactam and meropenem\/vaborbactam alone or in combination with polymyxin B against carbapenem resistant Acinetobacter baumannii","volume":"76","author":"Liang","year":"2023","journal-title":"J Antibiot (Tokyo)"},{"key":"2026011902093709100_dkaf495-B46","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3390\/antibiotics11020144","article-title":"Treatment of severe infections due to metallo-betalactamases Enterobacterales in critically ill patients","volume":"11","author":"Timsit","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"2026011902093709100_dkaf495-B47","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1093\/jac\/dkz497","article-title":"Pharmacokinetics and safety of aztreonam\/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study","volume":"75","author":"Cornely","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2026011902093709100_dkaf495-B48","doi-asserted-by":"publisher","first-page":"e02243-16","DOI":"10.1128\/AAC.02243-16","article-title":"Can ceftazidime-avibactam and aztreonam overcome \u03b2-lactam resistance conferred by metallo-\u03b2-lactamases in Enterobacteriaceae?","volume":"61","author":"Marshall","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026011902093709100_dkaf495-B49","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1093\/jac\/dkz532","article-title":"Metallo-\u03b2-lactamase resistance in Enterobacteriaceae is an artefact of currently utilized antimicrobial susceptibility testing methods","volume":"75","author":"Asempa","year":"2020","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/2\/dkaf495\/66444126\/dkaf495.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/2\/dkaf495\/66444126\/dkaf495.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T07:09:44Z","timestamp":1768806584000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkaf495\/8429095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1,19]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf495","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,1,19]]},"article-number":"dkaf495"}}